Cancer
A novel microbial mixture of 30 gut bacterial species, known as MET4, has been found to trigger an immune response in patients with cancer who are receiving immunotherapy. This breakthrough, discovered by researchers from the University Health Network's Toronto General Hospital Research Institute and Princess Margaret Cancer Centre,
Cancer
A phase 1-2 clinical trial has found that a genetically modified herpes simplex virus type 1 (HSV-1) can shrink tumors in one-third of patients with advanced melanoma, and nearly one out of six patients have seen tumors completely disappear. This innovative therapy, known as RP1, is a novel class of
Cancer
Researchers from Shenyang Pharmaceutical University have developed a novel approach to cancer gene therapy using bacteria-driven liposomes that synergize chemotherapy, ferroptosis, and immunotherapy for robust antitumor therapy. This innovative strategy has shown promise in enhancing the immunogenicity of tumor cells, triggering immunogenic cell death, and activating systemic antitumor immune responses.
Cancer research
A recent study published in Clinical Lung Cancer has investigated the real-world treatment response and outcomes of first-line nivolumab and ipilimumab plus chemotherapy (NIC) versus pembrolizumab plus chemotherapy (PC) in patients with PD-L1 negative metastatic non-small cell lung cancer (mNSCLC). The study, conducted at the St. Antonius Hospital in Utrecht,
Cancer research
Research from the Center for Cancer Biology at the University of South Australia has demonstrated the potential of Zirconium-89-labeled APOMAB to detect immune-mediated tumour cell death in vivo. The study, published in the Journal of Translational Medicine, found that APOMAB-immunoPET showed increased tumour uptake of 89Zirconium-labelled APOMAB after CAR-T cell
Cancer research
Researchers from the University of Michigan have published a groundbreaking study demonstrating that the combination of olaparib and radiotherapy can sensitize pancreatic cancer to immunotherapy. The study, which has been peer-reviewed and published in Molecular Cancer Therapeutics, reveals that the combination treatment enhances type I interferon (T1IFN)-mediated immune signaling,
Cancer
Researchers from Chung-Ang University have developed a novel core/shell nanocarrier that targets cancer cells by combining chemotherapy and immunotherapy, resulting in enhanced therapeutic outcomes. The nanocarrier, composed of M1 macrophage-derived vesicles coated with micelles loaded with 6-bromoindirubin-3 '-oxime (6BIO), was designed to overcome the limitations of conventional chemotherapy
Cancer research
Current research suggests that CD40 agonists, a type of immunotherapeutic agent, may be a promising approach to treating cancer. By licensing dendritic cells to prime tumor-specific T cells, polarizing macrophages to a proinflammatory phenotype, and activating B cells, CD40 agonists have shown significant potential in inducing antitumor immunity. However, clinical
Cancer
Researchers from Nankai University in Tianjin, People's Republic of China, have made a significant discovery in the field of cancer treatment. According to a new study published in Advanced Healthcare Materials, a new nanomedicine-based antitumor agent has been developed using traditional Chinese herbal medicine (TCHM). This innovative approach
Cancer
Research from Central South University, Hunan, People's Republic of China, has provided new insights into the role of the beta-2 adrenergic receptor (ADRB2) in regulating immune responses and its potential as a therapeutic target for cancer treatment. The study, published in the Journal for ImmunoTherapy of Cancer, found
Cancer
Cancer immunotherapy has revolutionized the treatment landscape of both hematological and solid cancers. However, despite initial success, T-cell-based adoptive cell transfer (ACT) therapies have been hindered by several obstacles, including a lack of antigen specificity, poor long-term survival of transplanted T cells, and a hostile tumor microenvironment. A team of
Cancer research
Cancer scientists at the National University of Singapore have made a groundbreaking discovery in the field of immunotherapy, developing a novel nanovaccine strategy to target and eliminate cancer stem cells, which cause tumour recurrence and incurability after surgery. The researchers, led by Dr. Gege Wu, propose a nanovaccine called NICER,
